GALACTIC-1: GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo-controlled phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks

All subjects enrolled into the study will have a diagnosis of IPF established within the previous five years, and a
diagnostic HRCT scan assessed according the ATS/ERS/Fleischner criteria available within the previous 12
months (up to 12 months +27 days). Evaluate the effect of GB0139 dry powder for inhalation compared with placebo over 52 weeks
treatment period on the annual rate of decline in FVC in participants with IPF who are not treated with
or cannot tolerate nintedanib or pirfenidone.